News
Abatacept vs. Upadacitinib in Biologic Refractory Rheumatoid Arthritis
NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had fewer safety signals and serious adverse events.
ICI Arthritis Tied to Cancer Progression
MedPage Today
Cancer patients treated with immune checkpoint inhibitors (ICI) who develop severe arthritis may be at risk for progression of the malignancy, a single-center study suggested.
COVID Transmission from Young to Old
The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots.
Tofacitinib and Thromboembolic Risk
Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (10 m
Thrombotic Risk in Rheumatoid Arthritis Linked to Disease Activity
A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA) and that risk is linked to RA disease activity.
Hydroxychloroquine Shows No Benefit in Hospitalized COVID-19 Patients
The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.
RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.
Biologics Beneficial in Eosinophilic Vasculitis
MedPage Today
Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.
Sustained Remission Off Therapy Unlikely in GPA
A French Vasculitis Study Group analysis of their granulomatosis with polyangiitis (GPA) reveals that after 10 years, only 7% of GPA patients achieved sustained remission off therapy (SROT) and have never relapsed.
IL-1 Inhibition Alters Arthroplasty Rates
A subanalysis of the CANTOS trial suggests that inhibition of interleukin-1β (IL-1β) can reduce rates of incident hip or knee replacement (THR/TKR) surgeries.
Fractures from Delays in Denosumab Reinfusions
Denosumab is effective in osteoporosis when used on schedue, but research suggests that discontinuation leads to rapid reversal of effect; a new observational study has shown that delays in denosumab administration of more than 16 weeks results in an increased vertebral fracture risk, according t
